Recent advances in the understanding of mastocytosis:: the role of KIT mutations

被引:179
作者
Orfao, Alberto
Garcia-Montero, Andres C.
Sanchez, Laura
Escribano, Luis
机构
[1] Univ Salamanca, CSIC, IBMCC, Dept Med, Salamanca 37007, Spain
[2] Univ Salamanca, CSIC, IBMCC, Serv Gen Citometria, Salamanca 37007, Spain
[3] Hosp Ramon & Cajal, Unidad Mastocitosis, Madrid, Spain
关键词
mastocytosis; SCF/Kit signalling pathway; KIT mutations; imatinib; tyrosine kinase inhibitors;
D O I
10.1111/j.1365-2141.2007.06619.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mastocytosis is a heterogeneous disorder characterised by the expansion and accumulation of mast cells in different organs and tissues. Mast cell physiology is closely dependent on activation of the stem cell factor/Kit signalling pathways and accumulating evidences confirm the physiopathological key role of activating KIT mutations (typically D816V) in mastocytosis and their relationship with the clinical manifestations of the disease. This paper reviews the most recent advances in the understanding of the molecular mechanisms associated with KIT mutations in mastocytosis, including recent data about the use of new therapies targeting the Kit molecule and its associated downstream signalling pathways.
引用
收藏
页码:12 / 30
页数:19
相关论文
共 170 条
[1]   Aberrant regulation of Wnt/beta-catenin pathway mediators in chronic myelogenous leukemia stem cells [J].
Abrahamsson, Annelie ;
Geron, Ifat ;
Gotlib, Jason ;
Durocher, Jeffrey ;
Creusot, Remi ;
Kavalerchik, Edward ;
Goff, Daniel ;
Fathman, C. G. ;
Lilleberg, Stanley L. ;
Giles, Francis ;
Weissman, Irving ;
Jamieson, Catriona .
BLOOD, 2006, 108 (11) :605A-605A
[2]   Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis [J].
Agis, H ;
Sotlar, K ;
Valent, P ;
Horny, HP .
LEUKEMIA RESEARCH, 2005, 29 (10) :1227-1232
[3]   A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib [J].
Akin, C ;
Fumo, G ;
Yavuz, AS ;
Lipsky, PE ;
Neckers, L ;
Metcalfe, DD .
BLOOD, 2004, 103 (08) :3222-3225
[4]  
Akin C., 2003, Journal of Allergy and Clinical Immunology, V111, pS206, DOI 10.1016/S0091-6749(03)80711-X
[5]   Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit [J].
Akin, C ;
Brockow, K ;
D'Ambrosio, C ;
Kirshenbaum, AS ;
Ma, YS ;
Longley, BJ ;
Metcalfe, DD .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (08) :686-692
[6]   Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome [J].
Alimena, G ;
Breccia, M ;
Mancini, M ;
Ferranti, G ;
De Felice, L ;
Gallucci, C ;
Mandelli, F .
LEUKEMIA, 2004, 18 (02) :361-362
[7]   The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors [J].
Andersson, J ;
Sjögren, H ;
Meis-Kindblom, JM ;
Stenman, G ;
Åman, P ;
Kindblom, LG .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (01) :15-22
[8]  
[Anonymous], 1869, Br Med J, V2, P323
[9]   Stat5 expression is required for IgE-mediated mast cell function [J].
Barnstein, Brian O. ;
Li, Geqiang ;
Wang, Zhengqi ;
Kennedy, Sarah ;
Chalfant, Charles ;
Nakajima, Hiroshi ;
Bunting, Kevin D. ;
Ryan, John J. .
JOURNAL OF IMMUNOLOGY, 2006, 177 (05) :3421-3426
[10]   EXPRESSION OF STEM-CELL FACTOR AND ITS RECEPTOR BY HUMAN NEUROBLASTOMA-CELLS AND TUMORS [J].
BECK, D ;
GROSS, N ;
BROGNARA, CB ;
PERRUISSEAU, G .
BLOOD, 1995, 86 (08) :3132-3138